Bristol Myers Squibb’s Reblozyl Meets Primary Endpoints as First-Line Treatment of MDS
November 2nd 2022Phase 3 trial evaluated luspatercept-aamt and shows highly statistically significant and clinically meaningful improvement in red blood cell transfusion for those with myelodysplastic syndromes.
Read More